Revvity Inc. (NYSE:RVTY) Receives $116.62 Average Target Price from Brokerages

Shares of Revvity Inc. (NYSE:RVTY) have been given a consensus recommendation of “Moderate Buy” by the fifteen ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, five have given a hold recommendation and nine have assigned a buy recommendation to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $116.6154.

A number of brokerages recently weighed in on RVTY. Stifel Nicolaus decreased their price objective on shares of Revvity from $120.00 to $110.00 and set a “hold” rating for the company in a report on Tuesday, July 29th. Guggenheim began coverage on shares of Revvity in a report on Wednesday. They issued a “neutral” rating for the company. Raymond James Financial restated an “outperform” rating and issued a $115.00 price objective (down from $120.00) on shares of Revvity in a report on Tuesday, July 29th. Bank of America decreased their price objective on shares of Revvity from $110.00 to $99.00 and set a “buy” rating for the company in a report on Monday, September 22nd. Finally, Barclays cut their target price on shares of Revvity from $110.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, October 2nd.

Revvity Price Performance

RVTY stock opened at $93.60 on Friday. Revvity has a 52-week low of $81.36 and a 52-week high of $129.50. The firm has a market capitalization of $10.86 billion, a price-to-earnings ratio of 39.66, a PEG ratio of 3.12 and a beta of 0.98. The firm has a 50 day moving average price of $88.59 and a 200-day moving average price of $92.30. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.75 and a current ratio of 3.33.

Revvity (NYSE:RVTY) last announced its quarterly earnings data on Monday, July 28th. The company reported $1.18 earnings per share for the quarter, topping analysts’ consensus estimates of $1.14 by $0.04. Revvity had a net margin of 10.19% and a return on equity of 7.66%. The company had revenue of $720.28 million during the quarter, compared to analyst estimates of $711.26 million. During the same period in the previous year, the business earned $1.22 EPS. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis. Revvity has set its FY 2025 guidance at 4.850-4.950 EPS. Equities research analysts forecast that Revvity will post 4.94 EPS for the current fiscal year.

Revvity Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, November 7th. Stockholders of record on Friday, October 17th will be given a dividend of $0.07 per share. The ex-dividend date of this dividend is Friday, October 17th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.3%. Revvity’s payout ratio is presently 11.86%.

Institutional Investors Weigh In On Revvity

A number of hedge funds have recently modified their holdings of RVTY. CYBER HORNET ETFs LLC bought a new stake in shares of Revvity during the 2nd quarter valued at $32,000. MUFG Securities EMEA plc bought a new stake in shares of Revvity during the 2nd quarter valued at $34,000. UMB Bank n.a. grew its position in shares of Revvity by 138.8% during the 2nd quarter. UMB Bank n.a. now owns 406 shares of the company’s stock valued at $39,000 after acquiring an additional 236 shares during the period. CVA Family Office LLC grew its position in shares of Revvity by 79.0% during the 2nd quarter. CVA Family Office LLC now owns 410 shares of the company’s stock valued at $40,000 after acquiring an additional 181 shares during the period. Finally, New Age Alpha Advisors LLC bought a new position in Revvity in the 1st quarter worth $44,000. Institutional investors own 86.65% of the company’s stock.

Revvity Company Profile

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.